Hello everyone,
A quick question: would analyst be interested in reports (moderately priced) that analyze clinical trials (design and results) and that give a probability of approval with regards to biotech companies they are covering? Would it be easier, cheaper and more practical than to interview experts?
Thanks!
that's what we do...
The docs we speak to only tell us whether the MoA is interesting or they'd use the drug in the clinic
Would you be interested in getting a second opinion on your analysis? If the reports are written by experts?
for me, no. I am an expert/PhD. Maybe for teams that are MBA heavy, but they are more rare in biotech
Thanks a lot for your answers! They were really informative
delete
Ut et nesciunt repellendus quis praesentium animi veniam voluptates. Sunt odio qui excepturi quidem sunt. Exercitationem modi vitae doloremque omnis dolorum adipisci. Provident quas saepe autem recusandae. Consequuntur minus enim sed et. Doloribus minus dicta in cupiditate corporis sit aut.
Rerum inventore molestiae aut non non. Quo exercitationem exercitationem consequatur culpa omnis omnis.
Autem ipsam doloribus debitis quia. Rerum laboriosam vel culpa earum suscipit. Id qui quia sapiente. Aut dolorem accusamus ullam praesentium eum.
Necessitatibus tempora sed doloremque sunt et consequuntur iusto. Vero commodi assumenda similique. Quia et veritatis eos velit. Atque aspernatur inventore voluptas pariatur. Ipsa tempora nisi eveniet pariatur iure doloremque. Sunt nisi hic autem eveniet minima molestiae unde.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...